Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'D2-DOPAMINE RECEPTOR OCCUPANCY' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 114 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Sethi, KD
      Movement disorders induced by dopamine blocking agents

      SEMINARS IN NEUROLOGY
    2. Garcia-Anaya, M; Apiquian, R; Fresan, A
      Atypical anti-psychotics: review article.

      SALUD MENTAL
    3. Williams, R
      Optimal dosing with risperidone: Updated recommendations

      JOURNAL OF CLINICAL PSYCHIATRY
    4. Kapur, S
      Neuroimaging and drug development: An algorithm for decision making

      JOURNAL OF CLINICAL PHARMACOLOGY
    5. Talvik, M; Nordstrom, AL; Nyberg, S; Olsson, H; Halldin, C; Farde, L
      No support for regional selectivity in clozapine-treated patients: A PET study with [C-11]raclopride and [C-11]FLB 457

      AMERICAN JOURNAL OF PSYCHIATRY
    6. Stip, E
      Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    7. Dean, CE
      Severe self-injurious behavior associated with treatment-resistant schizophrenia: Treatment with maintenance electroconvulsive therapy

      JOURNAL OF ECT
    8. Fitzgerald, PB; Kapur, S; Caligiuri, MP; Jones, C; Silvestri, S; Remington, G; Zipursky, RB
      Instrumentally detected changes in motor functioning in patients with low levels of antipsychotic dopamine D-2 blockade

      NEUROPSYCHOPHARMACOLOGY
    9. Patat, A
      Clinical pharmacology of psychotropic drugs

      HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    10. Kapur, S; Wadenberg, ML; Remington, G
      Are animal studies of antipsychotics appropriately dosed?: Lessons from the bedside to the bench

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    11. Saleem, A; Aboagye, EO; Price, PM
      In vivo monitoring of drugs using radiotracer techniques

      ADVANCED DRUG DELIVERY REVIEWS
    12. Kapur, S; Zipursky, R; Jones, C; Remington, G; Houle, S
      Relationship between dopamine D-2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia

      AMERICAN JOURNAL OF PSYCHIATRY
    13. Bartenstein, P; Grunwald, F; Kuwert, T; Tatsch, K; Sabri, O; Benkert, O; Fahlbusch, R; Grunder, G; Herholz, K; Weiller, C
      Clinical applications of single photon emission tomography in neuromedicine - Part 2: dementia, psychotic disorders, inflammation, trauma

      NUKLEARMEDIZIN-NUCLEAR MEDICINE
    14. Remington, G; Chong, SA
      Conventional versus novel antipsychotics: changing concepts and clinical implications

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    15. Perlmutter, JS; Moerlein, SM
      PET measurements of dopaminergic pathways in the brain

      QUARTERLY JOURNAL OF NUCLEAR MEDICINE
    16. Aman, MG; Madrid, A
      Atypical antipsychotics in persons with developmental disabilities

      MENTAL RETARDATION AND DEVELOPMENTAL DISABILITIES RESEARCH REVIEWS
    17. Breier, A; Su, TP; Malhotra, AK; Elman, I; Adler, CM; Weisenfeld, NI; Pickar, D
      Effects of atypical antipsychotic drug treatment on amphetamine-induced striatal dopamine release in patients with psychotic disorders

      NEUROPSYCHOPHARMACOLOGY
    18. Zhang-Wong, J; Zipursky, RB; Beiser, M; Bean, G
      Optimal haloperidol dosage in first-episode psychosis

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    19. Costa, DC; Pilowsky, LS; Ell, PJ
      Nuclear medicine in neurology and psychiatry

      LANCET
    20. Fitzgerald, P
      Long-acting antipsychotic medication, restraint and treatment in the management of acute psychosis

      AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
    21. BRYANT CA; JACKSON SHD
      FUNCTIONAL IMAGING OF THE BRAIN IN THE EVALUATION OF DRUG RESPONSE AND ITS APPLICATION TO THE STUDY OF AGING

      Drugs & aging
    22. SHARP HM; HEALY D; FEAR CF
      SYMPTOMS OR SIDE-EFFECTS - METHODOLOGICAL HAZARDS AND THERAPEUTIC PRINCIPLES

      Human psychopharmacology
    23. LEWIS R
      TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN ADOLESCENT SCHIZOPHRENIA - EFFICACY, TOLERABILITY, AND DIFFERENTIAL SENSITIVITY TO EXTRAPYRAMIDAL SYMPTOMS

      Canadian journal of psychiatry
    24. REMINGTON G; KAPUR S; ZIPURSKY R
      THE RELATIONSHIP BETWEEN RISPERIDONE PLASMA-LEVELS AND DOPAMINE D-2 OCCUPANCY - A POSITRON EMISSION TOMOGRAPHIC STUDY

      Journal of clinical psychopharmacology
    25. MONLEON S; VINADERCAEROLS C; PARRA A
      SEX-DIFFERENCES IN ESCAPE-AVOIDANCE RESPONSE IN MICE AFTER ACUTE ADMINISTRATION OF RACLOPRIDE, CLOZAPINE, AND SCH-23390

      Pharmacology, biochemistry and behavior
    26. Kuwert, T; Bartenstein, P; Grunwald, F; Herholz, K; Larisch, R; Sabri, O; Biersack, HJ; Moser, E; Muller, HW; Muller-Gartner, HW; Schober, O; Schwaiger, M; Bull, U; Heiss, WD
      Clinical significance of positron emission tomography in neuromedicine. A position paper on the results of an interdisciplinary consensus conference

      NERVENARZT
    27. REMINGTON G; KAPUR S; ZIPURSKY RB
      PHARMACOTHERAPY OF FIRST-EPISODE SCHIZOPHRENIA

      British Journal of Psychiatry
    28. REMINGTON G; KAPUR S; ZIPURSKY R
      APA PRACTICE GUIDELINE FOR SCHIZOPHRENIA - RISPERIDONE EQUIVALENTS

      The American journal of psychiatry
    29. BARTLETT EJ; BRODIE JD; SIMKOWITZ P; SCHLOSSER R; DEWEY SL; LINDENMAYER JP; RUSINEK H; WOLKIN A; CANCRO R; SCHIFFER W
      EFFECT OF A HALOPERIDOL CHALLENGE ON REGIONAL BRAIN METABOLISM IN NEUROLEPTIC-RESPONSIVE AND NONRESPONSIVE SCHIZOPHRENIC-PATIENTS

      The American journal of psychiatry
    30. CORYELL W; MILLER DD; PERRY PJ
      HALOPERIDOL PLASMA-LEVELS AND DOSE OPTIMIZATION

      The American journal of psychiatry
    31. LIDOW MS; WILLIAMS GV; GOLDMANRAKIC PS
      THE CEREBRAL-CORTEX - A CASE FOR A COMMON SITE OF ACTION OF ANTIPSYCHOTICS

      Trends in pharmacological sciences
    32. HOLLOMAN LC; MARDER SR
      MANAGEMENT OF ACUTE EXTRAPYRAMIDAL EFFECTS INDUCED BY ANTIPSYCHOTIC-DRUGS

      American journal of health-system pharmacy
    33. SCHERER J; TATSCH K; ALBUS M; SCHWARZ J; MAGER T; OERTEL WH
      D-2-DOPAMINE-RECEPTOR OCCUPANCY DURING TREATMENT WITH HALOPERIDOL DECANOATE

      European archives of psychiatry and clinical neuroscience
    34. SCHLOSSER R; SCHLEGEL S; HIEMKE C; NICKEL O; BOCKISCH A; RAO ML; HAHN K
      [I-123] IBZM SPECT IN PATIENTS TREATED WITH TYPICAL AND ATYPICAL NEUROLEPTICS - RELATIONSHIP TO DRUG PLASMA-LEVELS AND EXTRAPYRAMIDAL SIDE-EFFECTS

      PSYCHIATRY RESEARCH-NEUROIMAGING
    35. FARDE L
      BRAIN IMAGING OF SCHIZOPHRENIA - THE DOPAMINE HYPOTHESIS

      Schizophrenia research
    36. HIRSCHOWITZ J; HITZEMANN R; PISCANI K; BURR G; FRECSKA E; CULLITON D; MANN M; CURTIS C
      THE DOSE REDUCTION IN SCHIZOPHRENIA (DORIS) STUDY - A FINAL REPORT

      Schizophrenia research
    37. HERTEL P; NOMIKOS GG; SCHILSTROM B; ARBORELIUS L; SVENSSON TH
      RISPERIDONE DOSE-DEPENDENTLY INCREASES EXTRACELLULAR CONCENTRATIONS OF SEROTONIN IN THE RAT FRONTAL-CORTEX - ROLE OF ALPHA(2)-ADRENOCEPTOR ANTAGONISM

      Neuropsychopharmacology
    38. REMINGTON GJ; PRENDERGAST P; BEZCHLIBNYKBUTLER KZ
      NEUROLEPTIC DOSING IN CHRONIC-SCHIZOPHRENIA - A 10-YEAR FOLLOW-UP

      Canadian journal of psychiatry
    39. CALABRESI P; DEMURTAS M; BERNARDI G
      THE NEOSTRIATUM BEYOND THE MOTOR FUNCTION - EXPERIMENTAL AND CLINICAL-EVIDENCE

      Neuroscience
    40. MILLER R
      DOSE-RESPONSE RELATIONSHIPS FOR THE ANTIPSYCHOTIC EFFECTS AND PARKINSONIAN SIDE-EFFECTS OF TYPICAL NEUROLEPTIC DRUGS - PRACTICAL AND THEORETICAL IMPLICATIONS

      Progress in neuro-psychopharmacology & biological psychiatry
    41. CARSON RE; BREIER A; DEBARTOLOMEIS A; SAUNDERS RC; SU TP; SCHMALL B; DER MG; PICKAR D; ECKELMAN WC
      QUANTIFICATION OF AMPHETAMINE-INDUCED CHANGES IN [C-11] RACLOPRIDE BINDING WITH CONTINUOUS-INFUSION

      Journal of cerebral blood flow and metabolism
    42. KING DJ
      GUIDELINES FOR THE USE OF ANTIPSYCHOTIC DRUG STUDIES IN HEALTHY-VOLUNTEERS

      JOURNAL OF PSYCHOPHARMACOLOGY
    43. BUSATTO GF; KERWIN RW
      PERSPECTIVES ON THE ROLE OF SEROTONERGIC MECHANISMS IN THE PHARMACOLOGY OF SCHIZOPHRENIA

      JOURNAL OF PSYCHOPHARMACOLOGY
    44. NYBERG S; FARDE L
      THE RELEVANCE OF SEROTONERGIC MECHANISMS IN THE TREATMENT OF SCHIZOPHRENIA HAS NOT BEEN CONFIRMED

      JOURNAL OF PSYCHOPHARMACOLOGY
    45. KOPALA LC
      CLINICAL-EXPERIENCE IN DEVELOPING TREATMENT REGIMENS WITH THE NOVEL ANTIPSYCHOTIC RISPERIDONE

      International clinical psychopharmacology
    46. FARDE L; MACK RJ; NYBERG S; HALLDIN C
      D-2 OCCUPANCY, EXTRAPYRAMIDAL SIDE-EFFECTS AND ANTIPSYCHOTIC DRUG-TREATMENT - A PILOT-STUDY WITH SERTINDOLE IN HEALTHY-SUBJECTS

      International clinical psychopharmacology
    47. ARNT J; SKARSFELDT T; HYTTEL J
      DIFFERENTIATION OF CLASSICAL AND NOVEL ANTIPSYCHOTICS USING ANIMAL-MODELS

      International clinical psychopharmacology
    48. CASEY DE
      WILL THE NEW ANTIPSYCHOTICS BRING HOPE OF REDUCING THE RISK OF DEVELOPING EXTRAPYRAMIDAL SYNDROMES AND TARDIVE-DYSKINESIA

      International clinical psychopharmacology
    49. MARCUS MM; NOMIKOS GG; MALMERFELT A; ZACHRISSON O; LINDEFORS N; SVENSSON TH
      EFFECT OF CHRONIC ANTIPSYCHOTIC DRUG-TREATMENT ON PREPROSOMATOSTATIN AND PREPROTACHYKININ-A MESSENGER-RNA LEVELS IN THE MEDIAL PREFRONTAL CORTEX, THE NUCLEUS-ACCUMBENS AND THE CAUDATE-PUTAMEN OF THE RAT

      Molecular brain research
    50. VALLABHAJOSULA S; HIRSCHOWITZ J; MACHAC J
      EFFECT OF HALOPERIDOL DOSE ON IODINE-123-IBZM BRAIN SPECT IMAGING IN SCHIZOPHRENIC-PATIENTS

      The Journal of nuclear medicine
    51. PILOWSKY LS; MULLIGAN RS; ACTON PD; ELL PJ; COSTA DC; KERWIN RW
      LIMBIC SELECTIVITY OF CLOZAPINE

      Lancet
    52. BERGSTROM M; WESTERBERG G; NEMETH G; TRAUT M; GROSS G; GREGER G; MULLERPELTZER H; SAFER A; ECKERNAS SA; GRAHNER A; LANGSTROM B
      MAO-A INHIBITION IN BRAIN AFTER DOSING WITH ESUPRONE, MOCLOBEMIDE ANDPLACEBO IN HEALTHY-VOLUNTEERS - IN-VIVO STUDIES WITH POSITRON EMISSION TOMOGRAPHY

      European Journal of Clinical Pharmacology
    53. OZDEMIR V; NARANJO CA; HERRMANN N; REED K; SELLERS EM; KALOW W
      PAROXETINE POTENTIATES THE CENTRAL-NERVOUS-SYSTEM SIDE-EFFECTS OF PERPHENAZINE - CONTRIBUTION OF CYTOCHROME P4502D6 INHIBITION IN-VIVO

      Clinical pharmacology and therapeutics
    54. DENCKER SJ; AXELSSON R
      OPTIMIZING THE USE OF DEPOT ANTIPSYCHOTICS

      CNS DRUGS
    55. CASEY DE
      EXTRAPYRAMIDAL SYNDROMES - EPIDEMIOLOGY, PATHOPHYSIOLOGY AND THE DIAGNOSTIC DILEMMA

      CNS DRUGS
    56. MARCUS MM; NOMIKOS GG; SVENSSON TH
      DIFFERENTIAL ACTIONS OF TYPICAL AND ATYPICAL ANTIPSYCHOTIC-DRUGS ON DOPAMINE RELEASE IN THE CORE AND SHELL OF THE NUCLEUS-ACCUMBENS

      European neuropsychopharmacology
    57. HIETALA J; SYVALAHTI E
      DOPAMINE IN SCHIZOPHRENIA

      Annals of medicine
    58. SCHLOESSER R; SIMKOWITZ P; BARTLETT EJ; WOLKIN A; SMITH GS; DEWEY SL; BRODIE JD
      THE STUDY OF NEUROTRANSMITTER INTERACTIONS USING POSITRON EMISSION TOMOGRAPHY AND FUNCTIONAL COUPLING

      Clinical neuropharmacology
    59. LAMMERTSMA AA; BENCH CJ; HUME SP; OSMAN S; GUNN K; BROOKS DJ; FRACKOWIAK RSJ
      COMPARISON OF METHODS FOR ANALYSIS OF CLINICAL [C-11] RACLOPRIDE STUDIES

      Journal of cerebral blood flow and metabolism
    60. SEDVALL GC
      NEUROBIOLOGICAL CORRELATES OF ACUTE NEUROLEPTIC TREATMENT

      International clinical psychopharmacology
    61. LINDSTROM LH; WIESELGREN IM
      SCHIZOPHRENIA AND ANTIPSYCHOTIC SOMATIC TREATMENT

      International journal of technology assessment in health care
    62. FARDE L
      THE ADVANTAGE OF USING POSITRON EMISSION TOMOGRAPHY IN DRUG RESEARCH

      Trends in neurosciences
    63. BARTLETT EJ; BRODIE JD; SIMKOWITZ P; DEWEY SL; RUSINEK H; VOLKOW ND; WOLF AP; SMITH G; WOLKIN A; CANCRO R
      TIME-DEPENDENT EFFECTS OF A HALOPERIDOL CHALLENGE ON ENERGY-METABOLISM IN THE NORMAL HUMAN BRAIN

      Psychiatry research
    64. VOLKOW ND; FOWLER JS; GATLEY SJ; LOGAN J; WANG GJ; DING YS; DEWEY S
      PET EVALUATION OF THE DOPAMINE SYSTEM OF THE HUMAN BRAIN

      The Journal of nuclear medicine
    65. KANE JM
      DRUG-THERAPY - SCHIZOPHRENIA

      The New England journal of medicine
    66. CHRISTIAN BT; LIVNI E; BABICH JW; ALPERT NM; DISCHINO DD; RUEDIGER E; SALAZAR DE; FORD NF; FISCHMAN AJ
      EVALUATION OF CEREBRAL PHARMACOKINETICS OF THE NOVEL ANTIDEPRESSANT DRUG, BMS-181101, BY POSITRON EMISSION TOMOGRAPHY

      The Journal of pharmacology and experimental therapeutics
    67. OWENS DGC
      ADVERSE-EFFECTS OF ANTIPSYCHOTIC AGENTS - DO NEWER AGENTS OFFER ADVANTAGES

      Drugs
    68. GRASBY P; MALIZIA A; BENCH C
      PSYCHOPHARMACOLOGY - IN-VIVO NEUROCHEMISTRY AND PHARMACOLOGY

      British Medical Bulletin
    69. KUPERBERG GR
      ADVANCES IN THE TREATMENT OF SCHIZOPHRENIA

      British journal of clinical practice
    70. VELAKOULIS D; PANTELIS C
      WHAT HAVE WE LEARNED FROM FUNCTIONAL IMAGING STUDIES IN SCHIZOPHRENIA- THE ROLE OF FRONTAL, STRIATAL AND TEMPORAL AREAS

      Australian and New Zealand Journal of Psychiatry
    71. PALAO DJ; ARAUXO A; HARO JM; BRUNET M; BERNARDO M
      THE RELATIONSHIP BETWEEN PLASMA HALOPERIDOL CONCENTRATIONS AND CLINICAL-RESULTS

      Archives of general psychiatry
    72. STONE CK; GARVER DL
      HALOPERIDOL DOSING STRATEGIES - REPLY

      The American journal of psychiatry
    73. BRODIE JD
      IMAGING FOR THE CLINICAL PSYCHIATRIST - FACTS, FANTASIES, AND OTHER MUSINGS

      The American journal of psychiatry
    74. AUZOU P; OZSANCAK C; HANNEQUIN D; MOORE N; AUGUSTIN P
      CLOZAPINE FOR THE TREATMENT OF PSYCHOSIS IN PARKINSONS-DISEASE - A REVIEW

      Acta neurologica Scandinavica
    75. KAPUR S
      5-HT2 ANTAGONISM AND EPS BENEFITS - IS THERE A CAUSAL CONNECTION

      Psychopharmacology
    76. BALANTGORGIA EA; BALANT LP
      THERAPEUTIC DRUG-MONITORING - RELEVANCE DURING THE DRUG-TREATMENT OF PSYCHIATRIC-DISORDERS

      CNS DRUGS
    77. FISHER RE; MORRIS ED; ALPERT NM; FISCHMAN AJ
      IN-VIVO IMAGING OF NEUROMODULATORY SYNAPTIC TRANSMISSION USING PET - A REVIEW OF RELEVANT NEUROPHYSIOLOGY

      Human brain mapping
    78. MELTZER HY
      ROLE OF SEROTONIN IN THE ACTION OF ATYPICAL ANTIPSYCHOTIC-DRUGS

      Clinical neuroscience
    79. CALEY CF; WEBER SS
      SULPIRIDE - AN ANTIPSYCHOTIC WITH SELECTIVE DOPAMINERGIC ANTAGONIST PROPERTIES

      The Annals of pharmacotherapy
    80. CHESI AJR; FEASEYTRUGER KJ; ALZHEIMER C; TENBRUGGENCATE G
      DOPAMINE AUTORECEPTOR SENSITIVITY IS UNCHANGED IN RAT NUCLEUS-ACCUMBENS AFTER CHRONIC HALOPERIDOL TREATMENT - AN IN-VIVO AND IN-VITRO VOLTAMMETRIC STUDY

      European journal of neuroscience
    81. SEDVALL G; PAULI S; KARLSSON P; FARDE L; NORDSTROM AL; NYBERG S; HALLDIN C
      PET IMAGING OF NEURORECEPTORS IN SCHIZOPHRENIA

      European neuropsychopharmacology
    82. ALTAMURA AC; TACCHINI GL; MAES M
      HALOPERIDOL PLASMA THRESHOLD LEVELS FOR RELAPSE PREVENTION IN SCHIZOPHRENIA - A STUDY WITH HALOPERIDOL DECANOATE

      European neuropsychopharmacology
    83. RING HA
      THE VALUE OF POSITRON EMISSION TOMOGRAPHY IN PSYCHOPHARMACOLOGY

      Human psychopharmacology
    84. WARING E
      THE PSYCHOBIOLOGY OF FIRST-EPISODE SCHIZOPHRENIA

      Canadian journal of psychiatry
    85. MOERLEIN SM; PERLMUTTER JS; WELCH MJ
      USP STANDARDS FOR RACLOPRIDE C-11 INJECTION

      Pharmacopeial forum
    86. SEDVALL G; PAULI S; FARDE L; KARLSSON P; NYBERG S; NORDSTROM AL
      RECENT DEVELOPMENTS IN PET SCAN IMAGING OF NEURORECEPTORS IN SCHIZOPHRENIA

      Israel journal of psychiatry and related sciences
    87. SCHLOSSER R; SCHLEGEL S
      D-2-RECEPTOR IMAGING WITH [I-123] IBZM AND SINGLE-PHOTON EMISSION TOMOGRAPHY IN PSYCHIATRY - A SURVEY OF CURRENT STATUS

      Journal of neural transmission
    88. CASEY DE
      MOTOR AND MENTAL ASPECTS OF EXTRAPYRAMIDAL SYNDROMES

      International clinical psychopharmacology

    89. CURRENT CONCEPTS IN SCHIZOPHRENIA - INTERNATIONAL SYMPOSIA REPORT NEWSTANDARDS FOR ASSESSMENT AND TREATMENT .1. PATHOPHYSIOLOGY RESEARCH PROMPTS ASSESSMENT UPDATES

      The Journal of clinical psychiatry
    90. PICKAR D
      PROSPECTS FOR PHARMACOTHERAPY OF SCHIZOPHRENIA

      Lancet
    91. HUGUELET P
      NEURO-IMAGING AND SCHIZOPHRENIA

      Evolution Psychiatrique
    92. STONE CK; GARVER DL; GRIFFITH J; HIRSCHOWITZ J; BENNETT J
      FURTHER EVIDENCE OF A DOSE-RESPONSE THRESHOLD FOR HALOPERIDOL IN PSYCHOSIS

      The American journal of psychiatry
    93. MORTIMER AM
      NEWER AND OLDER ANTIPSYCHOTICS - A COMPARATIVE REVIEW OF APPROPRIATE USE

      CNS DRUGS
    94. GOODWIN GM
      BRAIN IMAGING AND HUMAN PSYCHOPHARMACOLOGY

      Human psychopharmacology
    95. JALENQUES I; COUDERT AJ
      CLOZAPINE FOR THE TREATMENT OF LEVODOPA-INDUCED PSYCHOSIS AND DYSKINESIA IN PARKINSONS-DISEASE

      Irish journal of psychological medicine
    96. SEDVALL G
      BRAIN IMAGING IN PSYCHIATRY - FUTURE POSS IBILITIES

      Fortschritte der Neurologie, Psychiatrie
    97. VILLENEUVE A
      PATHOPHYSIOLOGY AND TREATMENT OF NEGATIVE SYMPTOMS

      Canadian journal of psychiatry
    98. SIGMUNDSON HK
      PHARMACOTHERAPY OF SCHIZOPHRENIA - A REVIEW

      Canadian journal of psychiatry
    99. KING DJ
      THE USE OF HIGH-DOSES OF NEUROLEPTICS - THE CURRENT SITUATION

      International clinical psychopharmacology
    100. SCHELLENBERG R; MILCH W; SCHWARZ A; SCHOBER F; DIMPFEL W
      QUANTITATIVE EEG AND BPRS DATA FOLLOWING HALDOL-DECANOATE(R) ADMINISTRATION IN SCHIZOPHRENICS

      International clinical psychopharmacology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/02/20 alle ore 03:19:24